Kedrion Biopharma is exploring a debt financing of around €2bn that could be used in part to fund a dividend payment to its shareholders, according to a report by Bloomberg citing unnamed people familiar with the matter.
The Italian blood plasma therapies specialist has been in discussions with private credit lenders over potential financing, the people said, asking not to be identified because the talks are private.
A transaction has not been finalised and Kedrion could ultimately decide agains...
Continue Reading
Sign up for FREE to read the full article and access 150K+ alternative investment headlines.
Alternative Investment News